Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTCAAVREM: Telitacicept in ANCA-associated Vasculitis
NCT05962840Phase 4Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Chinese SLE Treatment And Research Group. Started Jun 2023; status: recruiting.
02
Drugs
telitacicept
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05962840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962840.